Welcome to our dedicated page for Phio Pharmaceuticals SEC filings (Ticker: PHIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a 300-page biotech filing isn’t easy—especially when Phio Pharmaceuticals’ disclosures dive deep into RNAi chemistry, IND milestones and financing rounds. If you’ve ever searched the 10-K for cash-runway details or hunted through Form 4s to see when executives buy shares ahead of INTASYL trial data, you know the challenge.
Stock Titan solves that problem. Our AI reads every document the moment it hits EDGAR and delivers plain-English answers to the questions investors actually ask: “Phio Pharmaceuticals SEC filings explained simply” and “understanding Phio Pharmaceuticals SEC documents with AI.” Quickly jump from an “Item 1A-Risk Factors” headline to a one-sentence summary, or set real-time alerts for “Phio Pharmaceuticals Form 4 insider transactions real-time.” You’ll also find:
- Complete Phio Pharmaceuticals annual report 10-K simplified—cash burn, R&D spend and INTASYL pipeline updates distilled by AI.
- Every Phio Pharmaceuticals quarterly earnings report 10-Q filing with side-by-side trend charts.
- Immediate access to Phio Pharmaceuticals 8-K material events explained—from trial results to financing announcements.
- Detailed Phio Pharmaceuticals proxy statement executive compensation breakdowns.
The result: faster insight into PH-762 progress, better tracking of Phio Pharmaceuticals insider trading Form 4 transactions, and the context you need to act decisively. Whether you’re scanning Phio Pharmaceuticals earnings report filing analysis or monitoring Phio Pharmaceuticals executive stock transactions Form 4, our platform keeps you ahead of the curve—without wading through biotech jargon.
Form 4 filing – Old Second Bancorp Inc. (OSBC)
Executive Vice President Donald Pilmer reported routine, plan-related share allocations dated 30 June 2025. The transactions were coded “J,” indicating transfers pursuant to employee benefit plans rather than open-market activity.
- Profit Sharing Plan: 1 OSBC common share allocated at $0; post-transaction balance 181 shares held indirectly.
- 401-K Plan: 15 OSBC common shares allocated at $0; post-transaction balance 3,981 shares held indirectly.
- Other indirect holdings: 1,450 shares in spouse’s IRA.
- Direct holdings: 63,135 common shares.
- Restricted Stock Units: 38,718 RSUs reported as directly held.
Total beneficial ownership following the allocations is approximately 107,465 share equivalents (common + RSUs). No derivative securities were acquired or disposed of in this filing.
The filing reflects minimal incremental ownership change (16 shares) with no cash consideration, suggesting purely administrative updates under company retirement programs. There is no indication of market sentiment shift or strategic insider buying/selling. Impact on OSBC’s investment thesis is therefore expected to be neutral.
Form 3 Initial Statement of Beneficial Ownership filed by Lisa Cabott Carson for Phio Pharmaceuticals (NASDAQ: PHIO) on June 28, 2025, reporting her beneficial ownership position as of June 6, 2025.
Key details:
- Carson has been appointed as VP, Finance and Administration at Phio Pharmaceuticals
- Currently holds no beneficial ownership of any securities, either direct or indirect
- Filing includes no derivative securities ownership (options, warrants, etc.)
- Individual filing submitted with Power of Attorney documentation (Exhibit 24)
This Form 3 establishes the baseline ownership position for the new officer's future transaction reporting requirements under SEC Section 16(a).
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
What is the primary focus of Phio Pharmaceuticals Corp?
How does the INTASYL technology work?
Which therapeutic targets are addressed by Phio's pipeline?
What clinical trials is Phio currently engaged in?
How does Phio position itself within the competitive biotech industry?
What are the advantages of the INTASYL platform?
Who are some of Phio's research collaborators?
What role does PH-762 play in Phio's clinical program?
